Treatment and Vaccine for HIV
Cure is within reach!
Our client has developed a broadly neutralizing human monoclonal antibody (mAB) that has the capacity to kill 98% of the HIV isolates around the world. The antibody has the capacity to:
- effectively treat anyone who is HIV-infected
- prevent HIV mother-to-child transmission, and
- stop the spread of HIV infection
Unmet Needs and Business Opportunity
HIV /AIDS pandemic presents some sobering statistics:
- Today, there are an estimated million people in the world with HIV/AIDS
- The rate of newly infected people is 14,000 a day / 5 million a year
- HIV/AIDS related death rates are 8,000 per day / 3 million per year
- 1,600 children die from HIV/AIDS each year
- 25 million people have died of HIV-related medical issues since 1981
- Currently there are 15 million HIV/AIDS-related orphans worldwide
- The number of HIV/AIDS-related orphans is expected to surpass 25 million by 2010.
- In the United States, 1.2 million individuals are infected with HIV/AIDS
- In the United States, 44,000 more individuals in the U.S. are infected each year.
The human tragedy continues unchecked internationally.
Despite significant medical advances, including the use of additional anti-retroviral drugs and fast-tracked Federal Drug Administration (FDA) approval of protease inhibitors, the number HIV/AIDS cases continues to advance unrestrained, regardless of cultures, geography, and borders without boundaries. The continued increase in multi-drug cross-resistant HIV viral strains, which spawn pathogenic “super-viruses”, highlights the fact that current and new drug therapies against HIV/AIDS are not an effective long term medical solution. Although these chemotherapeutics have extended lives, they are not able to prevent viral infectivity from person-to-person and have done little to slow the advance of HIV/AIDS globally.
The Technology
Clone 3 mAB from this company targets epitope amino acid sequence (KLIC) which is identical in 80% of known HIV clinical isolates, and is homologously conserved in another 18% of clinical isolates. These data suggest that this Clone 3 mAB can neutralize 98% of HIV types worldwide. It neutralizes HIV viral subtypes prevalent in Africa , China , India , Southeast Asia , Middle East , North America , South America , Australia , and Western and Eastern Europe . Regardless of geographical location, HIV-seropositive individuals who are classified as long-term non-progressors (LTNPs) produce neutralizing anti-gp41 HIV antibodies (i.e., Clone 3 mABs), that bind to the linear amino acid peptide KLIC.
Due to the fact that Clone 3 is a human antibody, it can therefore provide a non-toxic therapy with minimal - if any- side effects. Currently, there are 1764 primary clinical HIV isolates globally identified and recorded in the U.S. Government’s Los Alamos National Laboratory HIV database. As the Clone 3 Antibody binds to a highly (98%) conserved region (amino acid sequence) on the surface of the virus, which is immutable across geographical boundaries around the world, Clone 3 can be a broadly effective therapeutic agent.
The company's Clone 3 Antibody can be used in a non-toxic passive immunotherapy to effectively treat the estimated 33 million HIV-infected individuals worldwide, resulting in a long-term remission and consequently eliminating the need to chronically administer highly toxic anti-retroviral [ARV] chemotherapeutic drugs. Chemotherapeutic drugs can be successfully administered for only a limited period of time because of high HIV mutation rate of the virus which diminishes ARV effectiveness against drug-induced resistant target sites, and also brecuase of known ARV drug toxicities.
Clone 3 anti-HIV/AIDS immunotherapeutics are therefore a superior alternative to chemotherapeutic anti-retroviral drugs, which are known to be highly toxic to patients and are responsible for spawning fatal drug-resistant forms of HIV internationally.
The following non-toxic immunotherapies:
- CLONE 3 Human Neutralizing Antibody - a fully human antibody for therapeutic use in passive immunotherapy to treat any HIV+ patient and achieve an “absolute zero viral-load” preventing viral infectivity from individual-to-individual
- CLONE 3 Paratope Entry-Fusion Inhibitor - a therapy derived from a subset of the CLONE 3 neutralizing Antibody’s molecular structure, provides the same treatment efficacy as the primary CLONE 3 Neutralizing Antibody, with reduced production costs and simplified administrative and storage protocols. This can be used in oral therapy
- CLONE 3 Epitope entry-fusion inhibitor - a therapy developed from a subset of the viral binding site on the HIV viral isolate specific to the Clone 3 Neutralizing Antibody. The Epitope Entry-Fusion Inhibitor provides the same treatment efficacy as the primary CLONE 3 Neutralizing Antibody. This can be used as an oral thereapy
- CLONE 3 Vaccine - an “active” immunotherapy that can provide prophylactic humoral protective along with sterile immunity prior to HIV/AIDS exposure (useable by the world population of 6.6 billion individuals).
The company's proprietary process of immortalizing human B-cells and stabilizing monoclonal antibody [mAB] production has developed the technology platform to generate fully human monoclonal antibodies for a number of diseases. It has produced antibodies for:
- HIV-1 Clone 3
- Rabies
- Influenza A
- Influenza B
- Tetanus
- Diphtheria
Moreover, the following are under development:
- HIV-2
- Anthrax
- Smallpox
- Bird Influenza
- Rh (+) auto-immune disease
Contact Us
Do contact us for more information on this technology and to connect with our client.